Journal article
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
Abstract
BACKGROUND: Effective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresectable non-small-cell lung cancer when given as maintenance therapy after chemoradiation.
METHODS: The phase 3 START trial was an international, randomised, double-blind trial that recruited patients with …
Authors
Butts C; Socinski MA; Mitchell PL; Thatcher N; Havel L; Krzakowski M; Nawrocki S; Ciuleanu T-E; Bosquée L; Trigo JM
Journal
The Lancet Oncology, Vol. 15, No. 1, pp. 59–68
Publisher
Elsevier
Publication Date
1 2014
DOI
10.1016/s1470-2045(13)70510-2
ISSN
1470-2045